siRNA沉默乳腺癌靶基因及递送治疗的研究进展  

Targets and delivery systems of small interfering RNA in breast cancer therapy

作　　者：薛嫚[1,2] 普天磊 贺婉红[2] 李芳[2] 张婷[2] 何晓山[1] 俸灵林[2] 陈建兴[2] Xue Man Pu Tianlei He Wanhong Li Fang Zhang Ting He Xiaoshan Feng Linglin Chen Jianxing(Yunnan University of Traditional Chinese Medicine, Kunming 650500, China （Xue M, Pu TL, He XS Shanghai Institute of Planned Parenthood Research, Key Laboratory of Contraceptives and Devices Research, Shanghai Engineer and Technology Research Center of Reproductive Health Drug and Deviees, Shanghai 200032, China （Xue M, Pu TL, He WH, Li F, Zhang T, Feng LL, Chen JX)

机构地区：[1]云南中医学院,昆明650500 [2]上海市计划生育科学研究所,国家人口和计划生育委员会计划生育药具重点实验室,上海生殖健康药具工程技术研究中心,200032

出　　处：《中华生殖与避孕杂志》2017年第3期255-260,共6页Chinese Journal of Reproduction and Contraception

基　　金：上海市科学技术委员会科研计划项目(14JC1492300);上海市科学技术委员会科研计划项目(14431902000);上海市卫生和计划生育委员会科研课题(20144Y0049)~~

摘　　要：乳腺癌是最常见的女性恶性肿瘤之一,其治疗仍然存在多药耐药、复发和转移等问题。近年来,小干扰RNA(small interfering RNA,siRNA)在乳腺癌的研究中应用广泛,并有望成为新型的靶向性基因药物。本文检索近十年来siRNA在乳腺癌治疗研究方面的相关文献,着重从siRNA沉默乳腺癌相关的靶基因,siRNA的递送载体以及siRNA联合化疗药物治疗乳腺癌的研究3个方面进行综述,以期为乳腺癌的研究提供新方法和新思路。Breast cancer is the most common invasive malignancy among females. In the treatment of breast cancer, multidrug resistance, recurrence and metastasis are still major obstacles leading to the failure of therapy. Small interfering RNA （siRNA）, a novel and promisng targeted gene drug, is applied widely for breast cancer research. This paper reviews and summarizes the targets of siRNA in breast cancer research, delivery systems of siRNA and the concomitant strategies by combining with chemotherapies agents, to provide references and strategies for the further breast cancer treatment.

关 键 词：SIRNA 乳腺癌 靶基因 递送载体 联合给药 

分 类 号：R737.9[医药卫生—肿瘤]